Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Vaped Cannabidiol in Cannabis Use Disorder

NCT07933081 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Vaped Cannabidiol in Cannabis Use Disorder
Lead sponsor
University Hospital, Bordeaux
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
March 30, 2030
Enrollment
242 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis use disorder

Arms

As registered; 2 arms.

  • Control group Placebo comparatorPlacebo Liquid

    The control group will use a placebo vape liquid with a choice of two flavors (cannabis or red berries)

  • Experimental group ExperimentalCBD vape liquid

    The intervention group will use a CBD vape liquid at 70 mg/ml with a choice of two flavors (cannabis or red berries)

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of patients with a reduction of at least 50% in the total reported amount of cannabis consumed - 12 weeks From baseline to 12 weeks

    Proportion of patients for whom the intervention was successful, defined as a reduction of at least 50% in the total reported amount of cannabis consumed (in grams) at the end of the 12-week follow-up period, compared to baseline.

Lead sponsor's other trials

University Hospital, Bordeaux, most recent start first.